Analyst Ratings For NASDAQ:AGLE – Aeglea Bio Therapeutics (NASDAQ:AGLE)
Today, BMO Capital Markets initiated coverage on NASDAQ:AGLE – Aeglea Bio Therapeutics (NASDAQ:AGLE) with a Outperform.
Some recent analyst ratings include
- 6/14/2018-BMO Capital Markets initiated coverage with a Outperform rating.
- 4/24/2018-Evercore ISI initiated coverage with a Outperform ➝ Outperform rating.
Recent Insider Trading Activity For NASDAQ:AGLE – Aeglea Bio Therapeutics (NASDAQ:AGLE)
NASDAQ:AGLE – Aeglea Bio Therapeutics (NASDAQ:AGLE) has insider ownership of 21.90% and institutional ownership of 38.79%.
- On 5/10/2018 Bioventures Ltd Novartis, Major Shareholder, sold 73,955 with an average share price of $10.12 per share and the total transaction amounting to $748,424.60.
- On 5/7/2018 Bioventures Ltd Novartis, Major Shareholder, sold 15,548 with an average share price of $10.11 per share and the total transaction amounting to $157,190.28.
- On 12/8/2017 Anthony G Quinn, CEO, bought 8,288 with an average share price of $4.96 per share and the total transaction amounting to $41,108.48.
- On 12/6/2017 Anthony G Quinn, CEO, bought 4,888 with an average share price of $4.92 per share and the total transaction amounting to $24,048.96.
- On 12/5/2017 Charles N York II, CFO, bought 25,959 with an average share price of $4.48 per share and the total transaction amounting to $116,296.32.
- On 12/4/2017 Anthony G Quinn, Director, bought 7,956 with an average share price of $4.98 per share and the total transaction amounting to $39,620.88.
- On 12/1/2017 Anthony G Quinn, Director, bought 4,100 with an average share price of $4.53 per share and the total transaction amounting to $18,573.00.
Recent Trading Activity for NASDAQ:AGLE – Aeglea Bio Therapeutics (NASDAQ:AGLE)
Shares of NASDAQ:AGLE – Aeglea Bio Therapeutics closed the previous trading session at 10.26 up +0.17 1.68% with shares trading hands.